WWHEOR, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA.
Global Regulatory Strategy and Policy, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA.
Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.
Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed ("Decision Aid," https://sn.pub/TpDjZx ) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making.
真实世界证据(RWE)越来越多地被用于补充临床试验数据以支持监管决策,并且在某些情况下,还被用于确定某种疗法的临床疗效。然而,RWE 的应用并非适用于所有监管提交,并且确定合适的应用场景可能具有挑战性。我们开发了一个交互式工具(“决策辅助工具”,https://sn.pub/TpDjZx),旨在通过基于特定监管目标(新产品批准、新适应症或额外临床数据的标签扩展、上市后要求)和 RWE 研究设计类型(外部对照、观察性研究、实用试验)组织先例案例,来帮助研究人员、行业和其他利益相关者识别可以从利用 RWE 中受益的监管情况,从而协助研究人员、行业和其他利益相关者识别可以从利用 RWE 中受益的监管情况。该工具还描述了确保适用数据和严格方法(例如,明确终点、最小化偏倚、数据完整性)的关键成功因素。该工具允许用户通过选择特定的监管目标和/或研究设计来浏览先例案例。该决策辅助工具支持 RWE 领域的监管活动,并鼓励在监管决策中进一步使用 RWE。